US2021294011A1PendingUtilityA1

Glutamate agents in the treatment of mental disorders

Assignee: UNIV YALEPriority: Apr 5, 2005Filed: Jun 4, 2021Published: Sep 23, 2021

Est. expiryApr 5, 2025(expired)· nominal 20-yr term from priority

Inventors:Vladimir Coric John H. Krystal Gerard Sanacora

H10F 39/8053H10F 39/024A61K 31/545A61K 31/425A61K 31/428A61K 31/198A61K 45/06G02B 5/281A61K 31/485A61K 31/43G02B 1/10G02B 5/285A61K 31/13A61P 25/00G02B 5/283H01L 27/14621H01L 27/14685

PatentIndex Score

Cited by

References

Claims

Abstract

Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.

Claims

exact text as granted — not AI-modified

1 - 34 . (canceled) 
     
     
         35 . A method for treating dementia in a patient in need thereof, comprising administering to the patient an effective amount of riluzole in a pharmaceutical dosage form in combination with at least one pharmaceutically acceptable carrier. 
     
     
         36 . The method according to claim  1  wherein said dosage form is an oral dosage form.

Join the waitlist — get patent alerts

Track US2021294011A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.